Can an antidiabetic dose of metformin inhibit the growth of cancer cells in patients with endometrial cancer? A new study published in the journal Cancer says yes. In this study, 31 endometrial cancer patients were given metformin (1500–2250mg/day) preoperatively for 4–6 weeks. Treatment with metformin led to an inhibition of endometrial cancer cell growth as evidenced by a decrease in DNA synthesis in sera and a significant reduction in the Ki-67 and topoisomerase IIα labeling indices. This study confirms that further investigation into this treatment may be beneficial.
BACKGROUND Metformin, an antidiabetic drug, decreases the incidence of various cancers in diabetic patients. Because endometrial cancer is associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell growth in patients with endometrial cancer.
READ FULL ARTICLE
From Wiley Online Library
Please login or register first to view this content.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything MPR has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from MPR?
Register now at no charge to access unlimited daily drug news, medication safety alerts & recalls, and industry-supported drug information & education.
{{login-button}} {{register-button}}
Please login or register first to view this content.
